DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) announced a key milestone in its ACESOT-1051 clinical trial, as the ...

HPV driven cancers, including HPV+ HNSCC, are characterized by defects in the DDR pathway, making them potentially susceptible to WEE1 inhibition. HPV+ cancers are those where the underlying cause is ...

A patient with HPV-positive head and neck squamous cell carcinoma was dosed in a phase 1 clinical trial evaluating APR-1051.

By inhibiting WEE1, APR-1051 could potentially make cancer cells more susceptible to existing treatments, offering new hope for patients with few other options. Dr. Mirza’s extensive experience ...

Mindrank Ltd. has announced that the FDA has cleared the company’s IND application for MRANK-106, a potentially first-in-class, orally available dual inhibitor of WEE1 and YES1 kinases, for the ...

Zentalis ® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ...

This is the first patient to be dosed in Cohort 5 of the study, which involves a 70 mg once-daily dose of APR-1051, a WEE1 inhibitor. The study is evaluating APR-1051 in patients with advanced ...

Enter DNA-damage gatekeeper WEE1. Targeting this kinase can prevent DNA repair in cancer cells and speed them towards their demise — which is what researchers at Debiopharm hope their ...

ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 ...

Open label data from the study are expected in the second half of 2025. WEE1 inhibition has emerged as a promising strategy for targeting tumor cells with high replication stress and DNA damage ...

ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 2025 Twice daily (BID) dosing regimen in ongoing ...